Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress

Sep 20, 2017
4:30 PM ET




Stock Quote

NASDAQ: ARGS
1.45
+ 0.01 (+0.69%)

Day High:
1.49

Day Low:
1.41

Volume:
214,385

4:00 PM ET on Feb 16, 2018
Delayed at least 20 minutes.

Tweets